Please use this identifier to cite or link to this item: http://doi.org/10.25358/openscience-7438
Full metadata record
DC FieldValueLanguage
dc.contributor.authorKlöckner, Roman-
dc.contributor.authorWeinmann, Arndt-
dc.contributor.authorPrinz, Friederike-
dc.contributor.authorPinto dos Santos, Daniel-
dc.contributor.authorRuckes, Christian-
dc.contributor.authorDüber, Christoph-
dc.contributor.authorPitton, Michael Bernhard-
dc.date.accessioned2022-07-15T09:54:26Z-
dc.date.available2022-07-15T09:54:26Z-
dc.date.issued2015
dc.identifier.urihttps://openscience.ub.uni-mainz.de/handle/20.500.12030/7452-
dc.description.abstractBACKGROUND: To compare the overall survival of patients with hepatocellular carcinoma (HCC) who were treated with lipiodol-based conventional transarterial chemoembolization (cTACE) with that of patients treated with drug-eluting bead transarterial chemoembolization (DEB-TACE). METHODS: By an electronic search of our radiology information system, we identified 674 patients that received TACE between November 2002 and July 2013. A total of 520 patients received cTACE, and 154 received DEB-TACE. In total, 424 patients were excluded for the following reasons: tumor type other than HCC (n = 91), liver transplantation after TACE (n = 119), lack of histological grading (n = 58), incomplete laboratory values (n = 15), other reasons (e.g., previous systemic chemotherapy) (n =  114), or were lost to follow-up (n = 27). Therefore, 250 patients were finally included for comparative analysis (n = 174 cTACE; n = 76 DEB-TACE). RESULTS: There were no significant differences between the two groups regarding sex, overall status (Barcelona Clinic Liver Cancer classification), liver function (Child-Pugh), portal invasion, tumor load, or tumor grading (all p >  0.05). The mean number of treatment sessions was 4 ± 3.1 in the cTACE group versus 2.9 ± 1.8 in the DEB-TACE group (p = 0.01). Median survival was 409 days (95 % CI: 321–488 days) in the cTACE group, compared with 369 days (95 % CI: 310–589 days) in the DEB-TACE group (p = 0.76). In the subgroup of Child A patients, the survival was 602 days (484–792 days) for cTACE versus 627 days (364–788 days) for DEB-TACE (p = 0.39). In Child B/C patients, the survival was considerably lower: 223 days (165–315 days) for cTACE versus 226 days (114–335 days) for DEB-TACE (p = 0.53). CONCLUSION: The present study showed no significant difference in overall survival between cTACE and DEB-TACE in patients with HCC. However, the significantly lower number of treatments needed in the DEB-TACE group makes it a more appealing treatment option than cTACE for appropriately selected patients with unresectable HCC.en_GB
dc.description.sponsorshipDFG, Open Access-Publizieren Universität Mainz / Universitätsmedizinde
dc.language.isoengde
dc.rightsCC BY*
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/*
dc.subject.ddc610 Medizinde_DE
dc.subject.ddc610 Medical sciencesen_GB
dc.titleConventional transarterial chemoembolization versus drug-eluting bead transarterial chemoembolization for the treatment of hepatocellular carcinomaen_GB
dc.typeZeitschriftenaufsatzde
dc.identifier.doihttp://doi.org/10.25358/openscience-7438-
jgu.type.dinitypearticleen_GB
jgu.type.versionPublished versionde
jgu.type.resourceTextde
jgu.organisation.departmentFB 04 Medizinde
jgu.organisation.number2700-
jgu.organisation.nameJohannes Gutenberg-Universität Mainz-
jgu.rights.accessrightsopenAccess-
jgu.journal.titleBMC cancerde
jgu.journal.volume15de
jgu.pages.alternativeArt. 465de
jgu.publisher.year2015-
jgu.publisher.nameBioMed Centralde
jgu.publisher.placeLondonde
jgu.publisher.urihttp://dx.doi.org/10.1186/s12885-015-1480-xde
jgu.publisher.issn1471-2407de
jgu.organisation.placeMainz-
jgu.subject.ddccode610de
opus.date.modified2018-09-05T09:16:31Z
opus.subject.dfgcode00-000
opus.organisation.stringFB 04: Medizin: Klinik und Poliklinik für Diagnostische und Interventionelle Radiologiede_DE
opus.organisation.stringFB 04: Medizin: I. Medizinische Klinik und Poliklinikde_DE
opus.organisation.stringFB 04: Medizin: Interdisziplinäres Zentrum Klinische Studien Mainz (IZKS)de_DE
opus.identifier.opusid51989
opus.institute.number0419
opus.institute.number0425
opus.institute.number0460
opus.metadataonlyfalse
opus.type.contenttypeKeinede_DE
opus.type.contenttypeNoneen_EN
opus.affiliatedKlöckner, Roman
opus.affiliatedWeinmann, Arndt
opus.affiliatedPinto dos Santos, Daniel
opus.affiliatedRuckes, Christian
opus.affiliatedDüber, Christoph
jgu.publisher.doi10.1186/s12885-015-1480-xde
jgu.organisation.rorhttps://ror.org/023b0x485-
Appears in collections:DFG-OA-Publizieren (2012 - 2017)

Files in This Item:
  File Description SizeFormat
Thumbnail
conventional_transarterial_ch-20220714110410526.pdf744.56 kBAdobe PDFView/Open